In a previous study (Whitworth et al, 2005), we showed that in ovarian tumours the distribution of biologically active HS revealed by the colocalisation of FGF2 and the FGF-receptor probe (FR1c-AP) was confined to the tumour endothelium. Here, FGF2 is linked to neoplasm.